tirzepatide deadline compound Compounded medications are permitted by the FDA in times of shortage. That was The Tirzepatide Shortage Is Over:

In recent weeks, Novo Nordisk's commercial team increasingly pressured us to control clinical standards and steer patients to Wegovy regardless of whether it was clinically best for patients," Hims & Hers CEO Andrew Dedum wrote in a statement posted on X

Exendin-4 improves cardiovascular function and survival in flow-induced pulmonary hypertension

Calorie requirements are highly individualised and depend on multiple factors including age, sex, baseline weight, height, activity level, metabolic rate, and existing medical conditions

This innovative treatment works by addressing the hormones that regulate hunger and metabolism, making it easier to manage your appetite and support weight loss

TRANSCEND-T2D-1 reported results on March 19, 2026 the first Phase 3 diabetes readout: These trials are expected to further broaden retatrutide's potential label across metabolic, musculoskeletal, and liver disease indications